Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Oncodesign’s Chi-Mice® technology dedicated to the development of humanized preclinical models.
This is the best tool you can use to evaluate new therapeutic approaches in conditions that are as close as possible to a clinical situation:
More than 250 patient-derived xenografts (PDX) accessible in a database, including their pharmacological, histological, genome, molecular and clinical profile
Mouse models with humanized tissues from human stem cells: human immune system, human liver, human epithelial cells, human fibroblasts, human skin graft, microbiota
Full knowledge of a wide range of mouse strains: NSG, BRGS, NSG-SGM3, NOG, nude, SCID, immunocompetent, etc., as well as nude and immunocompetent rats
Biobank of samples: histological slides, serum from tumor-carrying mouse models, RNA and DNA extracts, cell lines derived from in vivo models, tumor stem cells and healthy tissues, patient clinical data
This technology is based on an international network of researchers and clinicians and the collection of biological samples from either healthy volunteers or willing patients, including for rare diseases, in compliance with ethical regulations.
Chi-Mice® is continuing to expand via developments within the IMODI personalized medicine unit.